8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 12, 2026·SEC
Gyre Therapeutics, Inc.(GYRE)Earnings, Financials & Key Ratios
GYRE•NASDAQ
$8.04
$780M mkt cap·357.3× P/E·Price updated May 6, 2026
AboutGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.Show more
- Revenue$117M+10.2%
- EBITDA$14M-21.1%
- Net Income$5M-58.4%
- EPS (Diluted)0.02-55.0%
- Gross Margin95.35%-1.0%
- EBITDA Margin12.01%-28.4%
- Operating Margin9.85%-35.5%
- Net Margin4.31%-62.3%
- ROE4.18%-80.6%
- ROIC8.87%-74.8%
- Debt/Equity0.01-59.4%
GYRE Key Insights
Gyre Therapeutics, Inc. (GYRE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 41.0%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GYRE Price & Volume
Gyre Therapeutics, Inc. (GYRE) stock price & volume — 10-year historical chart
Loading chart...
GYRE Growth Metrics
Gyre Therapeutics, Inc. (GYRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years52.18%
5 Years40.96%
3 Years4.46%
TTM10.24%
Profit CAGR
10 Years-
5 Years-
3 Years29.74%
TTM-58.4%
EPS CAGR
10 Years-
5 Years-
3 Years-9.14%
TTM662.5%
Return on Capital
10 Years-54.14%
5 Years-35.93%
3 Years-18.18%
Last Year9.05%
GYRE Recent Earnings
Gyre Therapeutics, Inc. (GYRE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (22%)●Beat Revenue 2/12 qtrs (33%)
Q2 2026Latest
Mar 12, 2026EPS
$0.04
Est $0.06
-29.4%
Revenue
$37M
Est $35M
+5.0%
Q4 2025
Nov 7, 2025EPS
$0.06
Est $0.05
+20.0%
Revenue
$31M
Est $36M
-15.8%
Q3 2025
Aug 11, 2025EPS
$0.02
Est $0.03
-33.3%
Revenue
$27M
Est $34M
-22.0%
Q2 2025
May 9, 2025EPS
$0.03
Est $0.03
+0.0%
Revenue
$22M
Est $29M
-23.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.04vs $0.06-29.4% | $37Mvs $35M+5.0% |
| Q4 2025 | Nov 7, 2025 | $0.06vs $0.05+20.0% | $31Mvs $36M-15.8% |
| Q3 2025 | Aug 11, 2025 | $0.02vs $0.03-33.3% | $27Mvs $34M-22.0% |
| Q2 2025 | May 9, 2025 | $0.03vs $0.03+0.0% | $22Mvs $29M-23.1% |
Based on last 12 quarters of dataView full earnings history →
GYRE Peer Comparison
Gyre Therapeutics, Inc. (GYRE) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | 8.25% | |
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.63B | 21.48 | 15.79 | 31.85% | 24.94% | 28.47% | 4.33% | 0.07 |
 INVA | 1.68B | 22.52 | 6.82 | 18.52% | 65.38% | 23.12% | 11.65% | |
 IDYA | 2.52B | 28.74 | -22.45 | 30.24% | -51.99% | -11.11% | 0.03 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 6.63B | 41.97 | 279.80 | 40.8% | 13.31% | 21.87% | 1.14 |
Compare GYRE vs Peers
Gyre Therapeutics, Inc. (GYRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GYRE Income Statement
Gyre Therapeutics, Inc. (GYRE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.02M | 6K | 0 | 20.95M | 7.34M | 102.29M | 113.45M | 105.76M | 116.59M |
| Revenue Growth % | 155.14% | -99.41% | -100% | - | -64.97% | 1293.98% | 10.91% | -6.78% | 10.24% |
| Cost of Goods Sold | 12.85M | 21.47M | 146K | 9.16M | 7.67M | 4.79M | 4.64M | 3.88M | 5.42M |
| COGS % of Revenue | 1261.98% | 357900% | - | 43.74% | 104.52% | 4.69% | 4.09% | 3.67% | 4.65% |
| Gross Profit | -11.83M▲ 0% | -21.47M▼ 81.5% | -146K▲ 99.3% | 11.79M▲ 8171.9% | -332K▼ 102.8% | 97.5M▲ 29466.6% | 108.81M▲ 11.6% | 101.87M▼ 6.4% | 111.17M▲ 9.1% |
| Gross Margin % | -1161.98% | -357800% | - | 56.26% | -4.52% | 95.31% | 95.91% | 96.33% | 95.35% |
| Gross Profit Growth % | -16.47% | -81.49% | 99.32% | 8171.92% | -102.82% | 29466.57% | 11.61% | -6.38% | 9.13% |
| Operating Expenses | 22.84M | 33.83M | 57.13M | 69.16M | 83.39M | 88.29M | 176.04M | 85.71M | 99.69M |
| OpEx % of Revenue | 2243.61% | 563800% | - | 330.13% | 1136.47% | 86.32% | 155.17% | 81.04% | 85.5% |
| Selling, General & Admin | 9.99M | 12.35M | 13.27M | 16.18M | 18.82M | 71.61M | 75.82M | 73.62M | 85.98M |
| SG&A % of Revenue | 981.63% | 205900% | - | 77.24% | 256.47% | 70% | 66.83% | 69.61% | 73.75% |
| Research & Development | 12.85M | 21.47M | 43.86M | 52.98M | 64.57M | 16.69M | 13.78M | 12.02M | 13.7M |
| R&D % of Revenue | 1261.98% | 357900% | - | 252.89% | 879.99% | 16.31% | 12.15% | 11.37% | 11.75% |
| Other Operating Expenses | 261K | 1.65M | 0 | 0 | 0 | 0 | 86.44M | 66K | 4K |
| Operating Income | -21.82M▲ 0% | -33.82M▼ 55.0% | -57.28M▼ 69.3% | -57.37M▼ 0.2% | -83.73M▼ 45.9% | 9.2M▲ 111.0% | -67.23M▼ 830.5% | 16.16M▲ 124.0% | 11.49M▼ 28.9% |
| Operating Margin % | -2143.61% | -563700% | - | -273.87% | -1140.99% | 9% | -59.26% | 15.28% | 9.85% |
| Operating Income Growth % | -6.88% | -54.99% | -69.35% | -0.16% | -45.94% | 110.99% | -830.52% | 124.04% | -28.93% |
| EBITDA | -21.65M | -33.67M | -57.13M | -57.23M | -83.44M | 10.33M | -66.12M | 17.75M | 14.01M |
| EBITDA Margin % | -2126.62% | -561216.67% | - | -273.21% | -1137.04% | 10.1% | -58.28% | 16.78% | 12.01% |
| EBITDA Growth % | -8.09% | -55.54% | -69.66% | -0.18% | -45.79% | 112.38% | -739.91% | 126.85% | -21.09% |
| D&A (Non-Cash Add-back) | 173K | 149K | 146K | 138K | 290K | 1.13M | 1.11M | 1.59M | 2.52M |
| EBIT | -21.56M | -30.05M | -55.18M | -56.24M | -87.93M | 9.2M | 19.21M | 16.23M | 11.49M |
| Net Interest Income | 0 | 0 | 2.15M | 561K | 39K | 726K | 1.04M | 1.55M | 1.75M |
| Interest Income | 261K | 3.77M | 2.15M | 561K | 39K | 726K | 1.04M | 1.55M | 1.75M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 261K | 3.77M | 2.1M | 1.13M | -4.21M | 209K | -9.73M | 7.05M | 2.95M |
| Pretax Income | -21.56M▲ 0% | -30.05M▼ 39.4% | -55.18M▼ 83.6% | -56.24M▼ 1.9% | -87.93M▼ 56.4% | 9.41M▲ 110.7% | -76.97M▼ 917.7% | 23.22M▲ 130.2% | 14.44M▼ 37.8% |
| Pretax Margin % | -2117.98% | -500916.67% | - | -268.48% | -1198.32% | 9.2% | -67.84% | 21.95% | 12.38% |
| Income Tax | -173K | 0 | 0 | -699K | 0 | 5.1M | 8.52M | 5.32M | -4.56M |
| Effective Tax Rate % | 0.8% | 0% | 0% | 1.24% | 0% | 54.16% | -11.06% | 22.91% | -31.56% |
| Net Income | -21.56M▲ 0% | -30.05M▼ 39.4% | -55.18M▼ 83.6% | -55.54M▼ 0.7% | -87.93M▼ 58.3% | 2.3M▲ 102.6% | -92.93M▼ 4137.1% | 12.09M▲ 113.0% | 5.03M▼ 58.4% |
| Net Margin % | -2117.98% | -500916.67% | - | -265.14% | -1198.32% | 2.25% | -81.92% | 11.43% | 4.31% |
| Net Income Growth % | -27.24% | -39.4% | -83.59% | -0.66% | -58.32% | 102.62% | -4137.05% | 113% | -58.4% |
| Net Income (Continuing) | -21.56M | -30.05M | -55.18M | -55.54M | -87.93M | 4.31M | -85.48M | 17.9M | 9.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 29.7M | 29.78M | 35.08M | 36.25M |
| EPS (Diluted) | -6.30▲ 0% | -2.68▲ 57.5% | -4.41▼ 64.6% | -2.93▲ 33.6% | -2.87▲ 2.0% | 0.03▲ 101.0% | -1.41▼ 4800.0% | 0.05▲ 103.5% | 0.02▼ 55.0% |
| EPS Growth % | 71.05% | 57.46% | -64.55% | 33.56% | 2.05% | 101.05% | -4800% | 103.55% | -55% |
| EPS (Basic) | -6.30 | -2.68 | -4.41 | -2.93 | -2.87 | 0.03 | -1.41 | 0.14 | 0.06 |
| Diluted Shares Outstanding | 3.42M | 11.21M | 12M | 19.18M | 30.64M | 75.69M | 65.83M | 102.29M | 103.18M |
| Basic Shares Outstanding | 3.42M | 11.21M | 12M | 19.18M | 30.64M | 76.74M | 65.83M | 85.09M | 89.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
GYRE Balance Sheet
Gyre Therapeutics, Inc. (GYRE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 39.11M | 123.99M | 96.07M | 89.51M | 51.48M | 49.65M | 57.22M | 64.79M | 102.37M |
| Cash & Short-Term Investments | 32.44M | 120.13M | 76.86M | 79.35M | 46.85M | 25.18M | 33.51M | 26.67M | 52.42M |
| Cash Only | 14.47M | 31.21M | 15.37M | 30.36M | 44.35M | 25.18M | 33.51M | 11.81M | 37.07M |
| Short-Term Investments | 17.97M | 88.91M | 61.5M | 48.99M | 2.5M | 0 | 0 | 14.86M | 15.36M |
| Accounts Receivable | 24K | 0 | 15M | 3.31M | 1.82M | 15.61M | 16.84M | 29.15M | 36.95M |
| Days Sales Outstanding | 8.61 | - | - | 57.73 | 90.43 | 55.72 | 54.18 | 100.62 | 115.67 |
| Inventory | 5.31M | 0 | 0 | 0 | 0 | 6.12M | 4.28M | 6.34M | 10.17M |
| Days Inventory Outstanding | 150.84 | - | - | - | - | 466.21 | 337.05 | 595.52 | 685.45 |
| Other Current Assets | 1.33M | 3.86M | 4.2M | 6.84M | 2.81M | 2.37M | 1.04M | 1.44M | 2.83M |
| Total Non-Current Assets | 404K | 929K | 2.49M | 5.34M | 4.19M | 35.1M | 59.32M | 60.62M | 63.76M |
| Property, Plant & Equipment | 276K | 386K | 2.23M | 2.27M | 3.71M | 18.38M | 23.78M | 25.7M | 24.73M |
| Fixed Asset Turnover | 3.69x | 0.02x | - | 9.25x | 1.98x | 5.57x | 4.77x | 4.12x | 4.71x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 1.86M | 1.7M | 1.71M | 4.73M |
| Long-Term Investments | 0 | 0 | 0 | 2.54M | 0 | 7.39M | 23.43M | 24.57M | 0 |
| Other Non-Current Assets | 128K | 543K | 257K | 528K | 472K | 7.47M | 5.72M | 3.03M | 27.43M |
| Total Assets | 39.51M▲ 0% | 124.92M▲ 216.1% | 98.55M▼ 21.1% | 94.85M▼ 3.8% | 55.66M▼ 41.3% | 84.75M▲ 52.3% | 116.54M▲ 37.5% | 125.41M▲ 7.6% | 166.13M▲ 32.5% |
| Asset Turnover | 0.03x | 0.00x | - | 0.22x | 0.13x | 1.21x | 0.97x | 0.84x | 0.70x |
| Asset Growth % | 3.74% | 216.15% | -21.11% | -3.76% | -41.31% | 52.26% | 37.5% | 7.61% | 32.48% |
| Total Current Liabilities | 8.74M | 4.8M | 28.9M | 17.8M | 14.16M | 12.24M | 20.05M | 19.52M | 18.29M |
| Accounts Payable | 747K | 1.25M | 4.28M | 5.93M | 6.42M | 122K | 355K | 108K | 124K |
| Days Payables Outstanding | 21.22 | 21.21 | 10.7K | 236.26 | 305.47 | 9.29 | 27.95 | 10.15 | 8.36 |
| Short-Term Debt | 5.08M | 0 | 483K | 663K | 1.98M | 0 | 0 | 0 | 636K |
| Deferred Revenue (Current) | 212K | 0 | 15M | 1.98M | 230K | 0 | 79K | 156K | 14K |
| Other Current Liabilities | 2.69M | 3.55M | 7.03M | 6.74M | 4.07M | 4.86M | 648K | 5.7M | 14.57M |
| Current Ratio | 4.48x | 25.83x | 3.32x | 5.03x | 3.63x | 4.06x | 2.85x | 3.32x | 5.60x |
| Quick Ratio | 3.87x | 25.83x | 3.32x | 5.03x | 3.63x | 3.56x | 2.64x | 2.99x | 5.04x |
| Cash Conversion Cycle | 138.22 | - | - | - | - | 512.63 | 363.28 | 685.99 | 792.76 |
| Total Non-Current Liabilities | 0 | 174K | 1.32M | 981K | 408K | 294K | 82.54M | 7.49M | 5.56M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 1.32M | 981K | 408K | 121K | 199K | 885K | 303K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 174K | 0 | 0 | 0 | 173K | 82.13M | 5.67M | 4.41M |
| Total Liabilities | 8.74M | 4.97M | 30.22M | 18.78M | 14.57M | 12.54M | 102.59M | 27M | 23.85M |
| Total Debt | 5.08M | 0 | 1.8M | 1.64M | 2.38M | 613K | 409K | 1.6M | 939K |
| Net Debt | -9.39M | -31.21M | -13.57M | -28.72M | -41.96M | -24.56M | -33.1M | -10.21M | -36.13M |
| Debt / Equity | 0.17x | - | 0.03x | 0.02x | 0.06x | 0.01x | 0.03x | 0.02x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | 0.06x | - | 0.09x | 0.07x |
| Net Debt / EBITDA | - | - | - | - | - | -2.38x | - | -0.58x | -2.58x |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 30.77M▲ 0% | 119.94M▲ 289.8% | 68.34M▼ 43.0% | 76.07M▲ 11.3% | 41.09M▼ 46.0% | 72.22M▲ 75.8% | 13.95M▼ 80.7% | 98.4M▲ 605.4% | 142.28M▲ 44.6% |
| Equity Growth % | 91.49% | 289.76% | -43.03% | 11.32% | -45.98% | 75.76% | -80.68% | 605.44% | 44.59% |
| Book Value per Share | 8.99 | 10.70 | 5.69 | 3.97 | 1.34 | 0.95 | 0.21 | 0.96 | 1.38 |
| Total Shareholders' Equity | 30.77M | 119.94M | 68.34M | 76.07M | 41.09M | 42.52M | -15.83M | 63.32M | 106.03M |
| Common Stock | 6K | 12K | 12K | 22K | 31K | 64K | 77K | 86K | 91 |
| Retained Earnings | -173.49M | -203.34M | -258.52M | -314.76M | -402.69M | 10.05M | -85.54M | -73.45M | -68.43M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -4K | 34K | 5K | 0 | -392K | 1.45M | 501K | 2.32M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 29.7M | 29.78M | 35.08M | 36.25M |
GYRE Cash Flow Statement
Gyre Therapeutics, Inc. (GYRE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -19.94M | -28.55M | -43.61M | -55.05M | -83.75M | 10.68M | 25.89M | -3.64M | 1.01M |
| Operating CF Margin % | -1958.74% | -475883.33% | - | -262.78% | -1141.39% | 10.44% | 22.82% | -3.44% | 0.87% |
| Operating CF Growth % | -7.95% | -43.19% | -52.74% | -26.22% | -52.15% | 112.75% | 142.5% | -114.06% | 127.74% |
| Net Income | -21.56M | -30.05M | -55.18M | -56.24M | -87.93M | 4.31M | -85.48M | 17.9M | 9.88M |
| Depreciation & Amortization | 173K | 149K | 146K | 138K | 290K | 1.13M | 1.11M | 1.59M | 2.48M |
| Stock-Based Compensation | 863K | 2.61M | 3.2M | 3.63M | 3.4M | 13.37M | 7.28M | 831K | 7.16M |
| Deferred Taxes | 0 | 0 | -11.42M | 0 | -3.89M | -838K | -1.16M | -1M | -1.11M |
| Other Non-Cash Items | 18K | 116K | 11.42M | 0 | 3.89M | 503K | 96.68M | -7.27M | -1.84M |
| Working Capital Changes | 567K | -1.37M | 8.21M | -2.57M | 483K | -7.8M | 7.46M | -15.69M | -15.55M |
| Change in Receivables | 7K | 0 | -15M | 11.69M | 1.5M | -7.92M | 1.3M | -9.29M | -11.95M |
| Change in Inventory | -479K | 0 | -490K | 0 | 3.88M | -879K | 1.75M | -2.14M | -3.63M |
| Change in Payables | -90K | 500K | 3.03M | 1.65M | 500K | -112K | 192K | -245K | 13K |
| Cash from Investing | -11.25M | -71.32M | 27.39M | 9.66M | 48.19M | -13.81M | -19.76M | -19.88M | -474K |
| Capital Expenditures | -23K | -376K | -64K | -267K | -839K | -4.99M | -8.52M | -2.31M | -1.19M |
| CapEx % of Revenue | 2.26% | 6266.67% | - | 1.27% | 11.43% | 4.87% | 7.51% | 2.19% | 1.02% |
| Acquisitions | 0 | 0 | -27.46M | 0 | 0 | -1.33M | 4.02M | -1.69M | 30K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -57K | -70.94M | 27.46M | 0 | 0 | -13K | 471K | -412K | 686K |
| Cash from Financing | 35.4M | 111.33M | 327K | 60.38M | 49.55M | 0 | 2.5M | 2.1M | 24.38M |
| Debt Issued (Net) | -14.32M | -5.08M | 0 | 0 | -6.7M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 35.4M | 116.41M | 327K | 60.38M | 49.55M | 0 | 2.5M | 773K | 25.86M |
| Dividends Paid | -3.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 18.27M | 0 | 0 | 0 | 6.7M | 0 | 0 | 1.33M | -1.49M |
| Net Change in Cash | 4.21M▲ 0% | 11.46M▲ 172.3% | -15.89M▼ 238.7% | 14.99M▲ 194.3% | 13.99M▼ 6.7% | -5.03M▼ 135.9% | 8.33M▲ 265.8% | -21.7M▼ 360.3% | 25.26M▲ 216.4% |
| Free Cash Flow | -19.96M▲ 0% | -28.93M▼ 44.9% | -43.68M▼ 51.0% | -55.31M▼ 26.6% | -84.59M▼ 52.9% | 5.68M▲ 106.7% | 17.31M▲ 204.7% | -6.77M▼ 139.1% | -180K▲ 97.3% |
| FCF Margin % | -1961% | -482150% | - | -264.06% | -1152.82% | 5.55% | 15.25% | -6.4% | -0.15% |
| FCF Growth % | -5.4% | -44.91% | -50.98% | -26.65% | -52.93% | 106.71% | 204.74% | -139.11% | 97.34% |
| FCF per Share | -5.83 | -2.58 | -3.64 | -2.88 | -2.76 | 0.08 | 0.26 | -0.07 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.95x | 0.79x | 0.99x | 0.95x | 4.64x | -0.28x | -0.30x | 0.20x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 6.35M | 8.52M | 0 |
GYRE Key Ratios
Gyre Therapeutics, Inc. (GYRE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -71.35% | -92.05% | -39.88% | -58.61% | -76.93% | -150.11% | 4.06% | -215.71% | 21.51% | 4.18% |
| Return on Invested Capital (ROIC) | -49.98% | -70.25% | -46.07% | -59.87% | -84.27% | -270.2% | 29.51% | -353.79% | 35.12% | 8.87% |
| Gross Margin | -2545.36% | -1161.98% | -357800% | - | 56.26% | -4.52% | 95.31% | 95.91% | 96.33% | 95.35% |
| Net Margin | -4246.87% | -2117.98% | -500916.67% | - | -265.14% | -1198.32% | 2.25% | -81.92% | 11.43% | 4.31% |
| Debt / Equity | 1.21x | 0.17x | - | 0.03x | 0.02x | 0.06x | 0.01x | 0.03x | 0.02x | 0.01x |
| FCF Conversion | 1.09x | 0.92x | 0.95x | 0.79x | 0.99x | 0.95x | 4.64x | -0.28x | -0.30x | 0.20x |
| Revenue Growth | -77.2% | 155.14% | -99.41% | -100% | - | -64.97% | 1293.98% | 10.91% | -6.78% | 10.24% |
GYRE SEC Filings & Documents
Gyre Therapeutics, Inc. (GYRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
GYRE Frequently Asked Questions
Gyre Therapeutics, Inc. (GYRE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Gyre Therapeutics, Inc. (GYRE) reported $116.6M in revenue for fiscal year 2025. This represents a 3019% increase from $3.7M in 2004.
Gyre Therapeutics, Inc. (GYRE) grew revenue by 10.2% over the past year. This is steady growth.
Yes, Gyre Therapeutics, Inc. (GYRE) is profitable, generating $5.0M in net income for fiscal year 2025 (4.3% net margin).
Dividend & Returns
Gyre Therapeutics, Inc. (GYRE) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
Gyre Therapeutics, Inc. (GYRE) had negative free cash flow of $0.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More GYRE
Gyre Therapeutics, Inc. (GYRE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates